Gene Regulation and Cancer

10th Anniversary of the AACR Special Conferences

October 14-18, 1998
The Homestead
Hot Springs, VA

CONFERENCE CO-CHAIRPERSONS
Phillip A. Sharp / Cambridge, MA
Jacqueline A. Lees / Cambridge, MA
Steven L. McKnight / Dallas, TX

CONFERENCE PROGRAM

Keynote Address
Leland H. Hartwell / Seattle, WA

Control of Cell Division and
Gene Expression
Jacqueline A. Lees / Cambridge, MA
Scott W. Lowe / Cold Spring Harbor, NY

Mechanisms of Transcriptional
Regulation
Jerry L. Workman / University Park, PA
Marian Carlson / New York, NY
David H. Price / Iowa City, IA

Growth Control and Chromatin
Acetylation
C. David Allis / Rochester, NY
Kevin Struhl / Boston, MA
Robert N. Eisenman / Seattle, WA
Michael Grunstein / Los Angeles, CA

Regulation of Cell Death
Albert S. Baldwin / Chapel Hill, NC

Developmental Biology and Gene
Regulation
Beverly M. Emerson / La Jolla, CA
Katia Georgopoulos / Cambridge, MA

Signal to Transcription
Steven L. McKnight / Dallas, TX
David J. Mangelsdorf / Dallas, TX
Gregg L. Semenza / Baltimore, MD

Gene Expression Technology
Stephen H. Friend / Seattle, WA

Additional Speakers to be Announced

Application Deadline: July 31, 1998

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org
PROTEASES AND PROTEASE INHIBITORS IN CANCER

Joint Conference of the
American Association for Cancer Research
and ACTA Pathologica
Microbiologica Immunologica Scandinavica

June 14-18, 1998
Nyborg Strand Hotel
Nyborg, Denmark

CONFERENCE CHAIRPERSONS
Lynn M. Matrisian / Nashville, USA
Keld Danø / Copenhagen, Denmark

SCIENTIFIC PROGRAM

Keynote Lectures
+*Henri Rochefort / Montpellier, France
*Alan Barrett / Cambridgeshire, England
Wolfram Bode / Martinsried, Germany
Zena Werb / San Francisco, USA

Molecular Mechanisms Regulating Protease Activity
+*Karl Trygvasson / Stockholm, Sweden
Judith S. Bond / Hershey, USA
+Bonnie F. Sloane / Detroit, USA
Gillian Murphy / Norwich, England
Carlos Lopez-Otin / Oviedo, Spain
David J. Loskutoff / La Jolla, USA

Proteases in Non-Neoplastic Processes
*Henning Birkedal-Hansen / Bethesda, USA
Christoph W. B. Peters / Freiburg, Germany
Peter Carmelet / Leuven, Belgium
Anne-Marie Mingers / Würzburg, Germany
Michael S. Pepper / Geneva, Switzerland
Carl-Erik H. Dempfle / Mannheim, Germany

Proteases in Cell Growth and Death
*Peter A. Andreasen / Aarhus, Denmark
Guy S. Salvesen / San Diego, USA
Joan V. Rudekrman / Boston, USA
Daniel B. Rifkin / New York, USA
Marcel Garcia / Montpellier, France
Francesco Blasi / Milano, Italy
Tyra Wolfsberg / Bethesda, USA

Proteases in Tumor Progression I
+*Jørgen Rygaard / Copenhagen, Denmark
Lynn M. Matrisian / Nashville, USA
+Yves A. De Clerck / Los Angeles, USA
Thomas H. Bugge / Cincinnati, USA
Keld Danø / Copenhagen, Denmark
Lars M. Holmgren / Stockholm, Sweden

Proteases in Tumor Progression II
*Edward Reich / New York, USA
Mina J. Bissell / Berkeley, USA
Paul Basset / Illkirch, France
Motoharu Seiki / Tokyo, Japan
+William G. Stetler-Stevenson / Bethesda, USA

Prognostic and Therapeutic Applications
+*Antti I. Vaheeri / Helsinki, Finland
John A. Foekens / Rotterdam, The Netherlands
+Nils Brünner / Copenhagen, Denmark
Steven Rosenberg / Emeryville, USA
Peter D. Brown / Oxford, England

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: April 30, 1998

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483 USA
215-440-9300 215-440-9313 (FAX)
e-mail: aacr@aacr.org
AACR Website: http://www.aacr.org

+ Indicates Members of the Organizing Committee
* Indicates Session Chairperson
22nd INTERNATIONAL BREAST CANCER RESEARCH CONGRESS OF THE IABCR

ATHENS 24-27 SEPTEMBER 1998
ASTIR PALACE RESORT, VOULIAGMENI

MAIN TOPICS

- Oncogenes and tumor suppressor genes associated with breast cancer
- Biology of breast cancer; progression from preneoplasia to metastasis
- Markers for breast cancer differentiation and malignancy
- Recent molecular biology findings in breast cancer
- Growth factors
- Hormones and breast cancer
- Immunology, immunotherapy and biological response modifiers in breast cancer
- Recent findings in epidemiology and control of breast cancer
- Current therapeutic management of breast cancer: surgery, radiotherapy, chemotherapy, hormonotherapy genetic intervention
- Chemoprevention
- Predictive and prognostic factors in breast cancer
- New and future therapeutic approaches in breast cancer
- Is axillary lymph node dissection essential in all breast cancer patients?
- Pitfalls in diagnosis and treatment. Underdiagnosis and overdiagnosis for malignancy.
- DCIS: Natural history and management.
Consider the image text for further information contact:
General Motors Cancer Research Foundation
C/o Campbell, Peachey & Associates
111 Quincy Place, N.E.
Washington, D.C. 20002
Telephone: (202) 636-8745
Fax: (202) 636-8755
Division of Medical Oncology—Vanderbilt Cancer Center: The Vanderbilt Cancer Center is recruiting an individual with a background in pharmacokinetic/pharmacodynamic analysis to help establish a Pharmacology Laboratory focused on the study of new anticancer agents. Startup funds will be provided to develop a core bioanalytical laboratory to support ongoing Phase I trials and a research program focused on mechanisms of drug action, metabolism, and/or drug resistance. The successful candidate must have an M.D., Ph.D., or Pharm.D. degree and must be able to interact with both clinical researchers and basic scientists. Faculty appointments will be in the Division of Medical Oncology, Clinical Pharmacology or both depending on qualifications. Interested individuals should call 615-322-4967 or send CV to Mace Rothenberg, M.D., Director, VCC Phase I Program, Division of Medical Oncology, 1956 The Vanderbilt Clinic, Vanderbilt University Medical Center, Nashville, TN 37232-5536. An equal opportunity/affirmative action employer.

POSTDOCTORAL POSITIONS in Cancer Genetics

Postdoctoral positions available for motivated individuals to study the genetics and molecular diagnosis of head and neck, lung, and bladder cancers in a highly productive laboratory. Ph.D. or equivalent training in molecular biology and human genetics preferred. Immediate openings available.

Please send a cover letter, curriculum vitae, and three letters of reference to:

Drs. David Sidransky and Jin Jen
Head and Neck Cancer Research Division
Johns Hopkins University School of Medicine
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
FAX: (410) 614-1411

CHAIRPERSON, DEPARTMENT OF CANCER GENETICS
Roswell Park Cancer Institute
Buffalo, NY

Roswell Park Cancer Institute is recruiting a Chairperson for the newly reorganized Department of Cancer Genetics. A record of outstanding research accomplishments and administrative experience and the vision to develop an outstanding center in cancer genetics are prerequisites. The support for this position is exceptional and includes the resources to recruit several new faculty. Prospective candidates must have a Ph.D and/or MD degree and an active research program within the broad field of cancer genetics.

Roswell Park Cancer Institute is a free-standing, NCI-designated Comprehensive Cancer Center that is nearing completion of a $250 million major modernization construction project. The Institute has six basic research departments, 11 clinical departments and a vibrant Graduate Studies Division within the State University of New York at Buffalo providing a highly interactive environment for collaborative research.

Interested individuals should submit their curriculum vitae and a one or two page summary of current research interests (before June 1, 1998) to:

Dr. Jane Clifford Azizkhan
Chairman, Search Committee for the Chair of Cancer Genetics
Professor, Department of Pharmacology and Therapeutics
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263

Roswell Park is a M/F/H/VI Affirmative Action Employer
The Cancer Institute of New Jersey, a nonprofit cancer care and research center that is only a little more than 6 years old, became the first cancer center in the state’s history to receive the coveted National Cancer Institute (NCI) Clinical Cancer Center designation.

In 1987, in recognition of a clear and pressing need for a New Jersey-based cancer center, and in an effort to take maximum advantage of the state’s remarkable assets, the New Brunswick Affiliated Hospitals, a consortium of Robert Wood Johnson University Hospital and St. Peter’s Medical Center, joined with the University of Medicine and Dentistry of New Jersey (UMDNJ) and the Robert Wood Johnson Medical School in the planning and implementation of The Cancer Institute of New Jersey. This major medical and scientific research complex is strategically located near the New Jersey Turnpike and the Garden State Parkway—and is no more than an hour’s drive from the largest population centers in the state. Furthermore, the New Brunswick site of the recently completed $26 million dollar treatment and research center of The Cancer Institute (cover) lies within the heart of New Jersey’s vast health and science resources, which encompass fourteen major pharmaceutical companies, numerous biotechnology firms, and a statewide system of first-class hospitals and health care facilities. Thus, all the people of New Jersey are assured access to the latest treatment options at a location near their home.

The New Brunswick facility is expected to become the nucleus of innovative cancer treatment and research in New Jersey. The 76,000 square-foot complex houses 22 research laboratories, outpatient care clinics for children and adults, and a sophisticated telecommunications system to support outreach and dialogue between The Cancer Institute and its network of partner and affiliate hospitals throughout the state.

The Institute’s network of partner hospitals has now grown to include the Atlantic Health System (Morristown Memorial Hospital, Overlook Hospital, and Mountainside Hospital); affiliate hospitals include: Jersey Shore Medical Center, Monmouth Medical Center, Raritan Bay Medical Center, Robert Wood Johnson University Hospital at Hamilton, and Southern Ocean County Hospital. Academic affiliates include: Cooper Hospital/University Medical Center and New Jersey Medical School.

The Cancer Institute’s current research programs include: Cancer Pharmacology, Carcinogenesis and Prevention, Cytokines and Signal Transduction, Transcriptional Regulation, Molecular Mechanisms, and Clinical Investigations. One of the key missions of The Cancer Institute is to investigate those cancers with a higher-than-average incidence in the state and to develop specific prevention programs as New Jersey ranks among the top states in the number of cancer cases diagnosed and in the number of deaths from cancer. Another key mission is education. As part of UMDNJ - Robert Wood Johnson Medical School and the state’s network of teaching hospitals, The Cancer Institute is also challenged with the task of training the next cadre of clinician/scientists, as well as oncology nurses, social workers, and other support staff.

Clinical multidisciplinary programs now include: The New Jersey Comprehensive Breast Care Center, the Pediatric Oncology Program, Genitourinary Oncology, Gynecological Oncology, Melanoma/Sarcoma, Hematological Malignancies and Transplantation, and many others. Clinical trials of experimental treatments currently include study protocols in such areas as: lymphoma, myeloma, and leukemia; lung, breast, prostate, ovarian, and colorectal cancers; and melanoma. These trials are open to all the people of New Jersey. The Cancer Institute’s multidisciplinary approach also enables patients to see physicians from several different specialties during one appointment and receive diagnosis and treatment options the same day.

William N. Hait (cover) is the Director of The Cancer Institute. A native New Jerseyan, Dr. Hait is a nationally recognized physician/scientist, noted for his research into the development of new cancer therapies. Before joining The Cancer Institute, he was an Associate Director of the Comprehensive Cancer Center at the Yale University School of Medicine. Dr. Hait earned his M.D. and Ph.D. degrees at the Medical College of Pennsylvania from 1972–1978. He has authored over 75 original research articles and 3 books. Among the honors he has received throughout his career are the Burroughs-Wellcome Clinical Pharmacology Award (1987), the American Federation for Clinical Research Award for Distinguished Service (1991), and a listing in every edition of The Best Doctors in America (Woodward/White, Inc.) from 1992–1997. He is the founding Editor of Cancer Therapeutics, which began publication in April 1998, and he is on the Editorial Boards of several journals, including serving as an Associate Editor for Clinical Cancer Research. He is a member of several professional societies, including the American Association for Cancer Research (AACR) since 1986. His service on AACR committees includes the Membership Committee (1991), Special Memberships Committee (1994), AACR/AACI Committee (1994–97), Education Committee (1996), Clinical Cancer Research Committee (1995), Program Committee [1997, 1998 (Modality-based Clinical Research Section Chairmanship, 1998)], Public Education Committee (1997–), and the State Legislative Committee Chairmanship for New Jersey (1997–).

We are obliged to Mr. Ernie Landante (PST Communications Group, Inc.) for his assistance in preparing this cover feature.

Sidney Weinhouse